Guide detail

Tesamorelin and Ipamorelin

This protocol outlines the safe and effective use of tesamorelin and ipamorelin for advanced users aiming to enhance growth hormone secretion, improve body composition, and support recovery. The combination leverages the synergistic effects of a GHRH analog (tesamorelin) and a GHRP analog (ipamorelin) for optimized results.

  1. Preparation: Ensure all materials are sterile. Reconstitute tesamorelin and ipamorelin with bacteriostatic water according to manufacturer instructions (typically 1-2 mL per vial). Store reconstituted peptides in the refrigerator (2-8°C).

  2. Dosage: Administer tesamorelin at 1-2 mg/day and ipamorelin at 200-300 mcg/day. Adjust based on tolerance and goals, but do not exceed 2 mg/day for tesamorelin or 300 mcg/day for ipamorelin.

  3. Timing: Inject subcutaneously in the morning (fasted) and/or post-workout. Avoid evening administration to prevent interference with natural GH pulsatility.

  4. Cycle Length: Use for 8-12 weeks, followed by a 4-week break to prevent desensitization. Monitor IGF-1 levels if possible.

  5. Injection Technique: Rotate injection sites (abdomen, thighs) to avoid lipodystrophy. Use insulin syringes (29-31G) for precise dosing.

  6. Post-Injection: Monitor for acute side effects (flushing, dizziness) and adjust dosage if needed. Avoid high-carb meals immediately after administration to maximize GH release.

  7. Synergistic Use: Tesamorelin (GHRH analog) enhances pituitary sensitivity, while ipamorelin (GHRP analog) amplifies GH pulse amplitude. This combination mimics natural GH secretion patterns.

  • This protocol is for advanced users with prior peptide experience. Beginners should start with monotherapy.
  • Pair with resistance training and adequate protein intake for optimal body composition effects.
  • Blood glucose monitoring is advised for diabetics or those with insulin resistance.
  • Discontinue use if persistent joint pain, edema, or carpal tunnel symptoms occur.

Warnings

  • Contraindicated in active cancer, pregnancy, or uncontrolled diabetes.
  • Avoid concurrent use with other GH-secretagogues (e.g., GHRP-6, MK-677) due to additive effects.
  • Prolonged use beyond 12 weeks may downregulate GH receptors.
  • Never share needles or vials to prevent infection.

References

  • Clinical studies on tesamorelin for visceral fat reduction (NIH, 2010)
  • Ipamorelin pharmacokinetics (J Clin Endocrinol Metab, 2005)
  • Peptide safety guidelines (International Peptide Society, 2022)